Plasma levels of interleukin‐6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study
Cancer · 2023
DOI: 10.1002/cncr.34784 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Jeanne S Mandelblatt und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Cancer Survivors, Hominidae. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIA NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
Immune activation/inflammation markers (immune markers) were tested to explain differences in neurocognition among older breast cancer survivors versus noncancer controls.
Methods
Women > 60 years old with primary breast cancer (stages 0–III) ( n = 400) were assessed before systemic therapy with frequency‐matched controls ( n = 329) and followed annually to 60 months; blood was collected during annual assessments from 2016 to 2020. Neurocognition was measured by tests of attention, processing speed, and executive function (APE). Plasma levels of interleukin‐6 (IL‐6), IL‐8, IL‐10, tumor necrosis factor α (TNF‐α), and interferon γ were determined using multiplex testing. Mixed linear models were used to compare results of immune marker levels by survivor/control group by time and by controlling for age, racial/ethnic group, cognitive reserve, and study site. Covariate‐adjusted multilevel mediation analyses tested whether survivor/control group effects on cognition were explained by immune markers; secondary analyses examined the impact of additional covariates (e.g., comorbidity and obesity) on mediation effects.
Results
Participants were aged 60–90 years (mean, 67.7 years). Most survivors had stage I (60.9%) estrogen receptor–positive tumors (87.6%). Survivors had significantly higher IL‐6 levels than controls before systemic therapy and at 12, 24, and 60 months ( p ≤ .001–.014) but there were no differences for other markers. Survivors had lower adjusted APE scores than controls ( p < .05). Levels of IL‐6, IL‐10, and TNF‐α were related to APE, with IL‐6 explaining part of the relationship between survivor/control group and APE ( p = .01). The magnitude of this mediation effect decreased but remained significant ( p = .047) after the consideration of additional covariates.
Conclusions
Older breast cancer survivors had worse long‐term neurocognitive performance than controls, and this relationship was explained in part by elevated IL‐6.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Georgetown University Medical Center, Georgetown University, Washington, DC, USA.
- Georgetown Lombardi Institute for Cancer and Aging Research, Georgetown University's Lombardi Comprehensive Cancer Center, Washington, DC, USA.
- Cancer Prevention and Control Program, Georgetown University's Lombardi Comprehensive Cancer Center, Washington, DC, USA.
- School of Aging Studies, University of South Florida, Tampa, Florida, USA.
- Department of Biostatistics, Bioinformatics, and Biomathematics, Department of Oncology and Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
- Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Jeanne S Mandelblatt, Xingtao Zhou, Zev M Nakamura, Traci N Bethea, Martine Extermann, Heather S L Jim, Sunita K Patel, Kelly E Rentscher, Kathleen Van Dyk, Judith E Carroll
Förderung
- NCI NIH HHS
- NIA NIH HHS
- NIH HHS
Zitieren
APA
Mandelblatt, J. S., Small, B. J., Zhou, X., Nakamura, Z. M., Cohen, H. J., Ahles, T. A., Ahn, J., Bethea, T. N., Extermann, M., Graham, D., Isaacs, C., Jacobsen, P. B., Jim, H. S. L., McDonald, B. C., Patel, S. K., Rentscher, K. E., Root, J. C., Saykin, A. J., Tometich, D. B., …, & Carroll, J. E. (2023). Plasma levels of interleukin‐6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study. Cancer. https://doi.org/10.1002/cncr.34784
Vancouver
Mandelblatt JS, Small BJ, Zhou X, Nakamura ZM, Cohen HJ, Ahles TA, et al. Plasma levels of interleukin‐6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study. Cancer. 2023. doi:10.1002/cncr.34784
BibTeX
@article{Mandelblatt2023,
author = {Mandelblatt, Jeanne S and Small, Brent J and Zhou, Xingtao and Nakamura, Zev M and Cohen, Harvey J and Ahles, Tim A and Ahn, Jaeil and Bethea, Traci N and Extermann, Martine and Graham, Deena and Isaacs, Claudine and Jacobsen, Paul B and Jim, Heather S L and McDonald, Brenna C and Patel, Sunita K and Rentscher, Kelly E and Root, James C and Saykin, Andrew J and Tometich, Danielle B and Van Dyk, Kathleen and Zhai, Wanting and Breen, Elizabeth C and Carroll, Judith E},
title = {Plasma levels of interleukin‐6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34784}
}
EUVIMED